You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advanced Prediction of Emerging Respiratory Decline with the Linshom Continuous Predictive Respiratory Sensor (CPRS)
SBC: LINSHOM MEDICAL INC Topic: NHLBIAbstract: This Fast-track SBIR application will fund and enable a new approach to respiratory monitoring, continuous predictive respiratory monitoring (CPRM), that stands to reduce morbidity and mortality due to respiratory compromise, while reducing health care system costs. Current devices and systems (human and machine) for respiratory monitoring are responsive by sounding a warning alarm when ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis
SBC: PROTHERA BIOLOGICS, INC. Topic: NICHDNecrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD
SBC: CREATIVE BIO-PEPTIDES INC Topic: NIA7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Mindfulness Based Stress Reduction App for African American Caregivers
SBC: COG ANALYTICS, LLC Topic: RAbstractThere are approximately 43.5 million informal (unpaid) caregivers in the U.S., of which 5.6 million are African American.1 Almost one third of people living with HIV/AIDS (PLWHA) report receiving care from informal caregivers, typically friends and family.2 Informal caregivers often provide a variety of support to PLWHA, including emotional and instrumental, financial assistance, and healt ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.
SBC: PREVEP, LLC Topic: NINDSAbstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis
SBC: Rise Therapeutics, LLC Topic: 300Project Summary The goal of this project is to develop a novel immunological-directed Live Biotherapeutic Product (LBP) that leverages natural microbiome pathways to inhibit gut inflammatory processes for the treatment of inflammatory bowel disease (IBD). Over 3 million adults in the U.S. suffer from IBD, an umbrella term encompassing two chronic inflammatory diseases of the gastrointestinal tract ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of PTLS-209 for treatment for giardiasis
SBC: PRIMETIME LIFE SCIENCES, LLC Topic: NIAIDProject Summary: This project focuses on the development of treatment to combat giardiasis resistance to standard care drugs. Giardia lamblia is a highly infective waterborne parasite that causes severe diarrhea. Current antigiardiasis drugs fail in about 20% of cases, and they all have undesirable side effects. Additionally, drug-resistant G. lamblia strains can be readily raised in the laborator ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: 100Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an innovative approach for in situ treatment of PCB impacted sediments by microbial bioremediation
SBC: REMBAC ENVIRONMENTAL, LLC Topic: 143PROJECT SUMMARY Polychlorinated biphenyls (PCBs) are one of the most problematic of legacy pollutants. Persistent and mobile in the environment, PCBs are largely ubiquitous in depositional sediments of aquatic systems in industrial regions of the United States. Their relatively high toxicity and bioaccumulation potential cause elevated risk to both human and ecological receptors. As such, PCBs are ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health